BR112022003687A2 - Método para tratar tinnitus, composição farmacêutica para administração intranasal, e, dose unitária pulverizável de ocitocina - Google Patents
Método para tratar tinnitus, composição farmacêutica para administração intranasal, e, dose unitária pulverizável de ocitocinaInfo
- Publication number
- BR112022003687A2 BR112022003687A2 BR112022003687A BR112022003687A BR112022003687A2 BR 112022003687 A2 BR112022003687 A2 BR 112022003687A2 BR 112022003687 A BR112022003687 A BR 112022003687A BR 112022003687 A BR112022003687 A BR 112022003687A BR 112022003687 A2 BR112022003687 A2 BR 112022003687A2
- Authority
- BR
- Brazil
- Prior art keywords
- oxytocin
- pharmaceutical composition
- unit dose
- sprayable
- intranasal administration
- Prior art date
Links
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 title abstract 5
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 title abstract 4
- 101800000989 Oxytocin Proteins 0.000 title abstract 4
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 4
- 229960001723 oxytocin Drugs 0.000 title abstract 4
- 208000009205 Tinnitus Diseases 0.000 title abstract 3
- 231100000886 tinnitus Toxicity 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000000203 mixture Substances 0.000 abstract 3
- 210000003928 nasal cavity Anatomy 0.000 abstract 1
- 239000002562 thickening agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Otolaryngology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962893363P | 2019-08-29 | 2019-08-29 | |
| PCT/US2020/048736 WO2021042029A1 (en) | 2019-08-29 | 2020-08-31 | Oxytocin compositions for treatment of tinnitus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022003687A2 true BR112022003687A2 (pt) | 2022-05-24 |
Family
ID=74680528
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022003687A BR112022003687A2 (pt) | 2019-08-29 | 2020-08-31 | Método para tratar tinnitus, composição farmacêutica para administração intranasal, e, dose unitária pulverizável de ocitocina |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11241477B2 (https=) |
| EP (1) | EP4021410A4 (https=) |
| JP (1) | JP2022546703A (https=) |
| AU (1) | AU2020335930B2 (https=) |
| BR (1) | BR112022003687A2 (https=) |
| CA (1) | CA3152988A1 (https=) |
| WO (1) | WO2021042029A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4299059A1 (en) | 2022-07-01 | 2024-01-03 | Labelic Analysis, S.L. | Composition for the treatment of tinnitus |
| US20250255930A1 (en) * | 2024-02-08 | 2025-08-14 | Maskbegone Llc | Methods of treatment of tinnitus using derivatives of oxytocin |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5276982B2 (ja) * | 2005-08-26 | 2013-08-28 | ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | オキシトシンの投与による頭痛の処置のための方法 |
| CN101677948A (zh) * | 2007-06-07 | 2010-03-24 | 纳斯泰克制药公司 | 卡贝缩宫素鼻用制剂和治疗孤独症的方法 |
| WO2011140608A1 (en) | 2010-05-14 | 2011-11-17 | Keating Charlotte L | Neuropsychopharmacological treatment regimes for treating psychological disorders |
| EP2571360A4 (en) * | 2010-05-19 | 2013-07-31 | Univ North Carolina | METHOD AND FORMULATIONS FOR OXYTOCIN TREATMENT OF DRUG ABUSE AND PSYCHIATRIC AND OTHER DISORDERS |
| US11744838B2 (en) * | 2013-03-15 | 2023-09-05 | Acerus Biopharma Inc. | Methods of treating hypogonadism with transnasal testosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event |
| US10940277B2 (en) | 2014-11-19 | 2021-03-09 | Optinose As | Intranasal administration |
| SG11201705591PA (en) * | 2015-01-07 | 2017-08-30 | Trigemina Inc | Magnesium-containing oxytocin formulations and methods of use |
-
2020
- 2020-08-31 AU AU2020335930A patent/AU2020335930B2/en not_active Expired - Fee Related
- 2020-08-31 EP EP20856513.5A patent/EP4021410A4/en active Pending
- 2020-08-31 JP JP2022513237A patent/JP2022546703A/ja not_active Ceased
- 2020-08-31 BR BR112022003687A patent/BR112022003687A2/pt unknown
- 2020-08-31 US US17/007,518 patent/US11241477B2/en active Active
- 2020-08-31 WO PCT/US2020/048736 patent/WO2021042029A1/en not_active Ceased
- 2020-08-31 CA CA3152988A patent/CA3152988A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021042029A1 (en) | 2021-03-04 |
| EP4021410A4 (en) | 2023-12-06 |
| AU2020335930B2 (en) | 2025-06-05 |
| AU2020335930A1 (en) | 2022-03-24 |
| US11241477B2 (en) | 2022-02-08 |
| CA3152988A1 (en) | 2021-03-04 |
| US20210060119A1 (en) | 2021-03-04 |
| EP4021410A1 (en) | 2022-07-06 |
| JP2022546703A (ja) | 2022-11-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20210368A (es) | Combinación de dextrometorfano y bupropión para el tratamiento de depresión | |
| AR060836A1 (es) | Un disco trans-mucosa para administrar un agente activo, una composicion trans-mucosa y el metodo de administracion obtenido | |
| BR112018013245A2 (pt) | método e aparelho para administração óxido nítrico com drogas suplementares | |
| BRPI0817396B8 (pt) | composição farmacêutica para tratar deficiência de vitamina b¹² | |
| HRP20230300T1 (hr) | Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije | |
| CO2022000016A2 (es) | Metodos para el tratamiento de la deficiencia de alfa-1 antitripsina (aatd) | |
| CL2021001636A1 (es) | Composición farmacéutica para el tratamiento de la hipertensión arterial pulmonar | |
| BR112012030641A2 (pt) | métodos e composições para terapia farmacêutica oral | |
| BR112020013750A8 (pt) | Dispensação intranasal de olanzapina por dispositivo olfativo de precisão | |
| BR112015026053A2 (pt) | composição farmacêutica, recipiente vedado, inalador dosimetrado, e, métodos para tratamento de um paciente sofrendo ou susceptível a sofrer de um distúrbio respiratório e para fabricação de uma composição farmacêutica | |
| BR112022003687A2 (pt) | Método para tratar tinnitus, composição farmacêutica para administração intranasal, e, dose unitária pulverizável de ocitocina | |
| AU2018282104A1 (en) | Use of vibegron to treat overactive bladder | |
| CL2024001175A1 (es) | Agente de arni para inhibir la expresión de un gen de metalopeptidasa de matriz 7. | |
| AR073796A1 (es) | Formulaciones de corticosteroides y sus metodos de tratamiento | |
| MX2023003097A (es) | Composiciones farmaceuticas que comprenden un oligonucleotido antisentido para administracion oral. | |
| EA202192328A1 (ru) | Комбинация назальной доставки генов и пероральной доставки коричной кислоты, олеамида или гемфиброзила для лечения лизосомных болезней накопления | |
| MX384760B (es) | Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco y gabapentina para el tratamiento del dolor neuropático. | |
| BR112021025291A2 (pt) | Dispositivos de contenção de medicamento e composições associadas | |
| MX2010013484A (es) | Formulaciones en dosis unitaria de ketorolaco para administración intra-nasal. | |
| BR112017022984A2 (pt) | dispositivo para facilitar o posicionamento de um cateter para administrar um medicamento em um paciente que esteja respirando espontaneamente | |
| BR112018008835A8 (pt) | composição farmacêutica oral, composição farmacêutica de liberação pulsátil oral, método para tratar uma condição de doença que requer terapia com fumarato de dimetila e método para tratar esclerose múltipla | |
| DOP2022000004A (es) | Composiciones farmacéuticas resistentes a la descarga de dosis que comprenden venirunad | |
| AR105087A1 (es) | Métodos para el tratamiento de mujeres con trastorno de deseo sexual hipoactivo (hsdd) con el tratamiento de combinación bupropión y trazodona | |
| BR112023026158A2 (pt) | Inibidores da recaptação de norepinefrina para tratamento da apneia do sono | |
| AR094287A1 (es) | Metodos y composiciones para administracion de oxibutinina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: MASKBEGONE LLC (US) |
|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |